1. Home
  2. MD vs NTLA Comparison

MD vs NTLA Comparison

Compare MD & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pediatrix Medical Group Inc.

MD

Pediatrix Medical Group Inc.

HOLD

Current Price

$23.42

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$15.52

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MD
NTLA
Founded
1979
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
MD
NTLA
Price
$23.42
$15.52
Analyst Decision
Hold
Buy
Analyst Count
4
23
Target Price
$20.50
$20.02
AVG Volume (30 Days)
580.5K
6.3M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
263.03
27.43
EPS
0.36
N/A
Revenue
$1,913,849,000.00
$67,671,000.00
Revenue This Year
$3.72
N/A
Revenue Next Year
$2.62
$62.75
P/E Ratio
$65.25
N/A
Revenue Growth
N/A
16.92
52 Week Low
$11.84
$7.95
52 Week High
$24.99
$28.24

Technical Indicators

Market Signals
Indicator
MD
NTLA
Relative Strength Index (RSI) 57.63 62.15
Support Level $21.05 $11.73
Resistance Level $24.02 $17.03
Average True Range (ATR) 0.67 1.31
MACD 0.13 0.28
Stochastic Oscillator 68.82 78.46

Price Performance

Historical Comparison
MD
NTLA

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: